MASE-T

MASE-T (Multiple Antigen-Specific Endogenously derived T cells) is an autologous adoptive cell therapy being developed for the treatment of metastatic melanoma. Developed at the National Center for Cancer Immune Therapy (CCIT-DK) under the leadership of Inge Marie Svane, this therapy utilizes T cells derived from the patient's peripheral blood rather than tumor-infiltrating lymphocytes (TILs). These T cells are expanded ex vivo using artificial antigen-presenting scaffolds (ImmPACT technology) designed to enrich for specificities against multiple tumor-associated antigens (TAAs) known to be expressed by melanoma cells. The treatment protocol typically involves lymphodepleting conditioning with cyclophosphamide and fludarabine followed by the infusion of the expanded T cells, often in combination with PD-1 checkpoint inhibitors like pembrolizumab to enhance anti-tumor activity and persistence. The approach aims to overcome the limitations of TIL therapy, such as the requirement for surgical tumor resection and the difficulty in expanding antigen-specific cells with high fitness.

Other names

Multiple Antigen-Specific Endogenously derived T cellsImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells